Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study

BMC Health Services ResearchBMC series – open, inclusive and trusted201717:353

https://doi.org/10.1186/s12913-017-2297-x

Received: 15 July 2016

Accepted: 8 May 2017

Published: 15 May 2017

Abstract

Background

Cervical cancer is currently the leading cause of cancer mortality among women in South Vietnam and the second leading cause of cancer mortality in North Vietnam. Human papillomavirus (HPV) vaccination has the potential to substantially decrease this burden. The World Health Organization (WHO) recommends that a cost-effectiveness analysis of HPV vaccination is conducted before nationwide introduction.

Methods

The Papillomavirus Rapid Interface for Modeling and Economics (PRIME) model was used to evaluate the cost-effectiveness of HPV vaccine introduction. A costing study based on expert panel discussions, interviews and hospital case note reviews was conducted to explore the cost of cervical cancer care.

Results

The cost of cervical cancer treatment ranged from US$368 – 11400 depending on the type of hospital and treatment involved. Under Gavi-negotiated prices of US$4.55, HPV vaccination is likely to be very cost-effective with an incremental cost per disability-adjusted life year (DALY) averted in the range US$780 - 1120. However, under list prices for Cervarix and Gardasil in Vietnam, the incremental cost per DALY averted for HPV vaccination can exceed US$8000.

Conclusion

HPV vaccine introduction appears to be economically attractive only if Vietnam is able to procure the vaccine at Gavi prices. This highlights the importance of initiating a nationwide vaccination programme while such prices are still available.

Keywords

Cost-effectiveness analysis Cervical cancer Vietnam PRIME Human papillomavirus

Background

Infection with human papillomavirus (HPV) is a cause of many diseases including cervical cancer. About 90 types of human papillomavirus have been found but two types (16 and 18) are responsible for 75% to 80% of cases of cervical cancer in Europe and North America [1], and more than 70% of cases in Asia [2]. In 2012, cervical cancer was the fourth most common type of cancer among women worldwide with an estimated 528,000 new cases and 266,000 deaths; 87% of deaths occurred in low and middle-income countries [3]. Treatment costs for cervical cancer remain high with low survival probabilities due to late diagnosis in many countries [4, 5]. HPV vaccines offer an approach for primary prevention of HPV infection that can eventually reduce the health and economic burden of cervical cancer. Cost-effectiveness studies in many countries using a range of model types have suggested that vaccinating young adolescent females can be cost-effective [612].

In Vietnam, there are no comprehensive national figures on cervical cancer incidence. However, studies based on smaller samples from older registry-based studies have found that incidence ranged from 6.8 cases per 100,000 women in the north of Vietnam [13] to 26 cases per 100,000 women in the south of Vietnam [14]. As estimated, cervical cancer is the main cause of female cancer mortality Ho Chi Minh City and the second main cause in Hanoi [15].

Vietnam began its accelerated transition policy from support from Gavi, the Vaccine Alliance, in 2016 [16]. While the country is no longer eligible for Gavi support, there is a window of opportunity where is can still procure vaccines at Gavi prices [17]. The Vietnam National Institute of Hygiene and Epidemiology (NIHE) remains keen on introducing additional vaccines despite tight resource constraints. Vietnam has not yet incorporated HPV vaccines into its routine vaccination schedule, although pilot studies have been conducted in the country [18]. A previous cost-effectiveness analysis concluded that HPV vaccination combined with regular screening could be cost-effective provided that vaccine prices were low (below I$25 per vaccinated girl) [19]. However, there has yet to be a cost-effectiveness study on HPV vaccination involving local analysts and stakeholders. There has also not been a study estimating the cost of cervical cancer and pre-cancer treatment in Vietnam, as the previous study extrapolated costing data from Thailand and other countries. Hence we aimed to perform the first local cost-effectiveness analysis of human papillomavirus vaccines in Vietnam using the Papillomavirus Rapid Interface for Modeling and Economics (PRIME).

Methods

Mathematical model

We used PRIME, a static model supported by the World Health Organization to facilitate estimating the cost-effectiveness of HPV vaccine introduction in order to support decisions about vaccine introduction, particularly in low and middle-income countries. An Excel-based interface to PRIME is available in the public domain (www.primetool.org) for country studies. This consists of a number of spreadsheets to input country-level data on demography, cervical cancer incidence and mortality, and costs. Outputs can be visualised in terms of tables and graphs. The Excel-based version of the model can be used to evaluate the cost-effectiveness of vaccinating females prior to sexual debut. Because it excludes herd effects and details of cancer natural history, it is not designed to evaluate other options such as vaccinating males, vaccinating older females, catch-up campaigns or changes to cervical cancer screening. The detailed model structure and assumptions have been previously described [20].

Methodological assumptions

Methodological assumptions used in the analysis followed WHO guidelines for cost-effectiveness evaluations [21]. In particular, we adopted a a discount rate of 3% for both costs and health effects on a lifetime time horizon. However, a health care provider perspective was adopted because of the unavailability of household expenses for cervical cancer patients in Vietnam. Health outcomes were measured in disability-adjusted life years (DALYs) rather than quality-adjusted life years (QALYs) because quality of life weights associated with cervical cancer have never been elicited from a Vietnamese population.

PRIME’s default data (obtained from publicly available databases and the literature) were used to inform parameters related to vaccine efficacy, population demography and cervical cancer incidence [20]. However, costs for vaccine delivery and cervical cancer treatment were estimated from primary sources.

Vaccination assumptions

School-based HPV vaccine demonstration projects organized by the Program for Appropriate Technology in Health (PATH) in Vietnam among 11 year olds achieved coverage of 96.1% [22]. Hence we assumed that vaccination would be delivered to 11 year olds and achieve 95% coverage. The current HPV vaccine schedule recommended by NIHE is three doses.

Vaccine delivery costs

We conducted a costing study which used a bottom-up approach to calculate the financial cost of HPV vaccine delivery from central to commune level (i.e. between NIHE in Hanoi, the provincial centers for preventive medicine, the district health centers, and the commune health station), incorporating both capital costs and recurrent costs. We also assumed minimal wastage of vaccine doses, due to annual training of vaccine delivery staff and use of single-dose vials in the Vietnamese national immunization program.

Financial costs estimated included both start-up and recurrent costs. Start-up costs were defined as initial investments whose benefits last longer than one year such as initial training, social mobilization, information, education and communication material development, cold chain equipment purchase and vehicles purchase. Recurrent costs were defined as the cost of resources whose benefits last one year or less such as the personnel time, transport, maintenance, monitoring and evaluation, and supervision as well as costs of short-term training activities that lasted a year or less.

Costs for healthcare personnel for each activity was estimated based on their time and monthly salary. To collect information related to these personnel costs, one staff member at each health facility was interviewed and monthly salary reports were collected. For start-up costs, we assumed a discount rate of 3% and useful lifecycle of 5-10 years.

Treatment costs

To estimate the cost of pre-cancer and cancer treatment, we conducted a study involving clinician and patient interviews, and hospital record reviews. This consisted of two phases.

Hospitals and health centers in Vietnam are stratified into four levels: central, provincial, district and commune. While provincial and district hospitals provide some treatment of pre-cancerous neoplasias, cervical cancer treatment is only provided at the central level. We randomly selected two central hospitals (Ho Chi Minh City Cancer Hospital and Hue Central Hospital) from a list of all hospitals in Ho Chi Minh City and Hue.

In phase I of the study, we invited healthcare workers from the selected hospitals to construct scenarios that represent patient treatment situations (see Table 1). In these hospitals, 40 staff from different departments (including examination, laboratory medicine, radiotherapy and chemotherapy) participated.
Table 1

Scenarios describing hospitalized cervical cancer patients for costing by the expert panel

Scenario

Hospital level

Diagnosis

Type of treatment

Length of treatment (days)

Number of days of productivity loss

Scenario 1

Central, provincial and district

CIN I

Annual screening

1

1

Scenario 2

Central, provincial and district

CIN I

Cryo therapy

2

3

Scenario 3

Central and provincial

CIN II & III

LEEP

4

5

Scenario 4

Central and provincial

CIN II &III

Conization

4

5

Scenario 5

At central level

IA1 - IIB proximal

Radical hysterectomy

7

7

Scenario 6

At central level

Radical hysterectomy + Chemoradiation

30

150

Scenario 7

At central level

Radical hysterectomy + Radio therapy (Intr)

30

150

Scenario 8

At central level

Radical hysterectomy + Radio-therapy (External beam)

30

150

Scenario 9

At central level

IIB distant - IVB

Chemoradiation

30

150

Scenario 10

At central level

Radio therapy (Intra + External)

30

150

Scenario 11

Average cost of scenario 5 to 10

In phase II, we micro-costed each of the scenarios identified by interviewing the healthcare workers in detail. In addition, we reviewed medical records and financial bills by randomly selecting 38 patients in the selected hospitals to extract information related to cancer stage, patient age, diagnosis, treatment and length of treatment. Further to that, we interviewed the 38 patients and their family members to get detailed costing information.

Sensitivity analysis

Model uncertainty was explored by varying parameters governing vaccine delivery and treatment costs according to the scenarios above. Vaccine prices were also varied between the Gavi negotiated price of United States Dollar (USD) 4.55 per dose, the market price of Cervarix in Vietnam of USD 35.60 per dose and the market price of Gardasil in Vietnam of USD 55.80 per dose.

Results

Table 2 shows the parameters used in the model, including birth cohort size, coverage of 3 vaccine doses, vaccine efficacy vs HPV 16/18, vaccine price per fully immunized girl, vaccine delivery cost per fully immunized girl, cancer treatment cost as per patient scenario, DALYs incurred due to non-fatal and fatal cancer episodes, and epidemiological data such as cervical cancer incidence and mortality. The female birth cohort size was 556,874 in 2014. Vaccine price per fully immunized girl was estimated to be USD 15-168. Cancer treatment cost for 10 patient scenarios ranged from USD 368-11448 depending on the kind of treatment. Information related to cervical cancer incidence and mortality was extracted from GLOBOCAN 2012. All-cause mortality in 2012 was extracted from national data.
Table 2

Selected parameters for estimating cost-effectiveness of HPV vaccination using the PRIME model

No

Parameter

Average value/value

Range

Source

1

Vaccine delivery cost per FIG

$ 10.4

$ 9.5-$ 11.3

Costing study

2

Cancer treatment cost

  

Costing study

 

Scenario 5 (IA1 - IIB proximal treated by Radical hysterectomy)

$ 368.3

N/A

 
 

Scenario 6 (IA1 - IIB proximal treated by Radical hysterectomy + Chemoradiation)

$ 8700.1

N/A

 
 

Scenario 7 (IA1 - IIB proximal treated by Radical hysterectomy + Radio therapy (Intr))

$ 2209.6

N/A

 
 

Scenario 8 (IA1 - IIB proximal treated by Radical hysterectomy + Radio-therapy (External beam))

$ 1449.9

N/A

 
 

Scenario 9 (IIB distant – IVB treated by Chemoradiation)

$ 11448.1

N/A

 
 

Scenario 10 (IIB distant – IVB treated by Radio therapy (Intra + External))

$ 5166.52

N/A

 
 

Scenario 11 (average cost of all scenarios)

$ 4,890.44

N/A

 

3

DALYs lost per non-fatal cancer episode

0.7

 

Literature review

4

DALYs lost per fatal cancer episode (excluding life years lost)

0.8

 

Literature review

5

Epidemiological data

  

Literature review

 

Cervical cancer incidence in 2012

6.1 per 100000

 

GLOBOCAN 2012

20.5 per 100000

26.7 per 100000

31.3 per 100000

32.1 per 100000

26.2 per 100000

20.5 per 100000

13 per 100000

 

Cervical cancer mortality in 2012

1.1 per 100000

 

GLOBOCAN 2012

6.5 per 100000

15.1 per 100000

18.8 per 100000

21.3 per 100000

21.8 per 100000

20 per 100000

16.1 per 100000

5.3 per 100000

 

All-cause mortality in 2012

100 - 52 800 per 100 000 (depending on age)

 

National statistics

Table 3 compares the cost-effectiveness of HPV vaccination in Vietnam under different assumptions about the cost of cervical cancer treatment (depending on the type of treatment and stage of cancer) and the cost of vaccination. If HPV vaccines can be procured at prices negotiated by Gavi, then the incremental cost per DALY averted ranges between USD18 (under scenario 9) - USD1,103 (under scenario 5). However, if either vaccine is only available at list prices, then the incremental cost per DALY averted increases dramatically, exceeding USD4,000 in all the scenarios explored. Using the average cost of cancer treatment over the six scenarios gives an incremental cost per DALY of USD800 at Gavi prices, and over USD5,000 at list prices.
Table 3

Estimation of incremental costs as per life saved, per life year saved and per DALY averted in the PRIME

Estimation of incremental costs

Vaccine price

Scenario 5

Scenario 6

Scenario 7

Scenario 8

Scenario 9

Scenario 10

Scenario 11 (average cost)

Incremental cost per discounted life saved

HPV vaccine with negotiated price from GAVI (13.65 US$ for 3 doses)

24,490

5,773

20,354

22,061

401

13,711

14,331

Cervarix vaccine with 106.8 US$ for 3 doses

122,510

103,793

118,374

120,081

97,619

111,731

112,351

Gardasil vaccine with 167.4 US$ for 3 doses

186,279

167,561

182,142

183,849

161,388

175,499

176,120

Incremental cost per discounted life year saved

HPV vaccine with negotiated price from GAVI (13.65 US$ for 3 doses)

1,196

282

994

1,077

20

670

700

Cervarix vaccine with 106.8 US$ for 3 doses

5,983

5,069

5,781

5,865

4,768

5,457

5,487

Gardasil vaccine with 167.4 US$ for 3 doses

9,098

8,184

8,896

8,979

7,882

8,571

8,602

Incremental cost per discounted DALY averted

HPV vaccine with negotiated price from GAVI (13.65 US$ for 3 doses)

1,103

260

917

994

18

618

645

Cervarix vaccine with 106.8 US$ for 3 doses

5,518

4,675

5,331

5,408

4,397

5,032

5,060

Gardasil vaccine with 167.4 US$ for 3 doses

8,390

7,547

8,203

8,280

7,269

7,904

7,932

Unit cost: US$

Discussion

Our analysis suggests that routine HPV vaccination of 11-year-old girls in Vietnam has an incremental cost-effectiveness ratio of around USD780 - 1200 per DALY averted and USD7000 - 23000 per life saved, if the vaccine can be procured at prices available to Gavi, the Vaccine Alliance. This is well below Vietnam’s Gross Domestic Product (GDP) per capita, and hence at the level commonly considered “very cost-effective” based on global recommendations in WHO-CHOICE.

There are large disparities in cervical cancer incidence between north and south Vietnam, so the cost-effectiveness of vaccination is likely to differ between regions. However, we have performed our analysis on a national level because the most recent cervical cancer incidence data is only available at the national-level, and because a national program is likely to be more acceptable to policy makers.

More recently, the use of GDP per capita-based thresholds for cost-effectiveness has been criticized [25] and is no longer recommended by WHO. Several alternatives have been suggested, including comparing the incremental cost-effectiveness of new interventions to existing interventions, and measuring the willingness to pay for health improvements. In terms of the first approach, the cost per disability-adjusted life year (DALY) averted of HPV vaccination is similar to previously published figures for rotavirus (USD540 per DALY averted) [23], and slightly lower than figures for Haemophilus influenza type b (USD1373 per DALY averted) [24]. The cost per life saved is within the range of estimates for corresponding figures for existing vaccines in Vietnam’s Expanded Programme on Immunization (USD1000 - 27,000 per life saved) [26, 27]. For the second approach, the only relevant study to refer to is one in a rural area of Vietnam in 2014. This revealed that respondents were willing to pay USD667 - 992 for a quality-adjusted life year (QALY) [28]. The results would likely be higher if urban respondents were surveyed. Nevertheless, the results suggest that HPV vaccination is likely to be cost-effective in Vietnam if the country is able to access Gavi prices, but the cost-effectiveness would probably not be favourable if higher prices had to be paid.

A study conducted to assess Vietnamese mothers’ willingness to pay for HPV vaccination for their daughters suggested that nearly 70% of them would pay for HPV vaccines at $7 per course, but this drops to 30% at $353 per course [29]. This suggests that even at Gavi-negotiated prices, public procurement of HPV vaccines is necessary in order to see substantial vaccine uptake in the population.

If Vietnam is not eligible to purchase vaccine prices at Gavi-negotiated levels, then vaccination appears much less cost-effective than other vaccines, and its incremental cost-effectiveness ratio well exceeds GDP per capita. This highlights the value of pooled procurement mechanisms such as those used by Gavi and the Pan-American Health Organization (PAHO) in obtaining fair prices in low- and lower-middle income countries [30]. It also underscores the urgency of HPV vaccine introduction in Gavi-graduating countries like Vietnam while they are still eligible for lower vaccine prices. Analyses such as these are also helpful to local policy makers for negotiating long-term prices with vaccine manufacturers. Further analyses could take into account constraints of both cost-effectiveness and affordability in different regions and socio-economic contexts in Vietnam.

Only one previous cost-effectiveness analysis of HPV vaccination in Vietnam has been conducted [19], which used an individual-based Monte Carlo simulation model developed at Harvard University. Like our analysis, the Harvard analysis concluded that HPV vaccination would only be cost-effective at low vaccine prices (below about $10 per vaccinated girl in north Vietnam and $50 in south Vietnam). The advantage of our study is that we were able to use actual vaccine prices available to Gavi and on the private market in Vietnam. We were also able to micro-cost cervical cancer treatment costs for the first time, instead of extrapolating costs from Thailand and other Asian countries as was done in the Harvard study.

Vietnam is one of the pioneer countries to use PRIME with WHO support to inform a national cost-effectiveness analysis of HPV vaccination. The tool was found by local analysts to have both positive features and shortcomings. Data and expertise requirements are light, facilitating its use and interpretation by non-experts. This allowed analyses to be led by local investigators in contrast to many previous cost-effectiveness analyses in low and middle-income countries [31]. However, PRIME underestimates the cost-effectiveness of HPV vaccination by not incorporating herd protection, pre-cancerous health states or non-cervical cancer disease outcomes such as anogenital warts. Also, the Excel-based version lacks built-in features for probabilistic sensitivity analysis, so outputs such as cost-effectiveness acceptability curves have to be constructed based on manual alteration of input parameters. Hence there is scope for future iterations of PRIME to incorporate more advanced features for expert users.

Conclusion

This is the first cost-effectiveness analysis of HPV vaccination in Vietnam to be led by local analysts and to include a local costing study of cervical cancer treatment. The study highlights the urgency of HPV vaccine implementation in Vietnam during the window of opportunity to obtain Gavi prices. It also demonstrates the importance of HPV vaccine introduction in Gavi-graduating countries before the countries become ineligible for low Gavi prices, after which the vaccination programme may cease to be cost-effective. Finally, our study highlights the need to understand realistic cost-effectiveness thresholds in low and middle-income countries so as to avoid misinforming health policy makers.

Abbreviations

DALY: 

Disability-adjusted life years

GDP: 

Gross domestic product

HPV: 

Human papillomavirus

NIHE: 

National Institute of Hygiene and Epidemiology

PAHO: 

Pan-American Health Organization

PATH: 

Program for Appropriate Technology in Health

PRIME: 

Papillomavirus Rapid Interface for Modelling and Economics (PRIME)

QALY: 

Quality-adjusted life years

USD: 

United States dollar

WHO-CHOICE: 

World Health Organization CHOosing Interventions that are Cost-Effective initiative

Declarations

Acknowledgements

We thank Phan Van Tuong and Ha Anh Duc for help with data collection. The PRIME model was developed by Mark Jit, Marc Brisson, Allison Portnoy and Raymond Hutubessy with the support of WHO.

Funding

Data collection for this research was supported by a grant from WHO. Mark Jit was supported by grants from WHO and Gavi, the Vaccine Alliance.

Availability of data and materials

PRIME is available at www.primetool.org. All data used in PRIME are included in this manuscript or in the original published article.

Authors’ contributions

HVM and MJ designed the overall study. HVM drew up the data collection plan and designed the data collection instruments. HVM and NTTM collected data from the study sites. NTTM and HVM analysed the data collected. HVM and NTTM used PRIME to conduct the cost-effectiveness analysis with guidance from MJ, the lead designer for PRIME. HVM, NTTM and MJ drafted the manuscript. All authors read and approved the final version of the manuscript. HVM is the guarantor.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Ethical clearance was obtained from the Institutional Review Board of Hanoi School of Public Health in Vietnam (reference number: 261/2015/YTCC-HD3). Informed consent was obtained from all respondents before conducting the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Hanoi University of Public Health
(2)
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine
(3)
Modelling and Economics Unit, Public Health England

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Du Cancer. 2010;127(12):2893–917.View ArticleGoogle Scholar
  2. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.View ArticlePubMedGoogle Scholar
  3. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 [Internet]. 2016 [cited Accessed 15 May 2016]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
  4. Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C. Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care. Womens Health Issues. 2010;20(6):400–5.View ArticlePubMedGoogle Scholar
  5. Novaes HM, Itria A, Silva GA, Sartori AM, Rama CH, Soarez PC. Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics (Sao Paulo, Brazil). 2015;70(4):289–95.View ArticleGoogle Scholar
  6. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine. 2008;26(49):6244–57.View ArticlePubMedGoogle Scholar
  7. Ezat WP, Aljunid S. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev. 2010;11(1):79–90.PubMedGoogle Scholar
  8. Rey-Ares L, Ciapponi A, Pichon-Riviere A. Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis. Arch Argent Pediatr. 2012;110(6):483–9.PubMedGoogle Scholar
  9. Ezat SW, Aljunid S. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev. 2010;11(4):943–51.PubMedGoogle Scholar
  10. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MK, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007;25(33):6257–70.View ArticlePubMedGoogle Scholar
  12. Kahn JA, Bernstein DI. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol. 2005;17(5):476–82.View ArticlePubMedGoogle Scholar
  13. Anh PT, Parkin DM, Hanh NT, Duc NB. Cancer in the population of Hanoi, Vietnam, 1988-1990. Br J Cancer. 1993;68(6):1236–42.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Nguyen QM, Nguyen HC, Parkin DM. Cancer incidence in Ho Chi Minh City, Viet Nam, 1995-1996. Int J Cancer. 1998;76(4):472–9.View ArticlePubMedGoogle Scholar
  15. Domingo EJ, Noviani R, Noor MR, Ngelangel CA, Limpaphayom KK, Thuan TV, et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine. 2008;26 Suppl 12:M71–9.View ArticlePubMedGoogle Scholar
  16. Countries eligible for support 2016 [Internet]. 2016 [cited Accessed 20 May 2016]. Available from: http://www.gavi.org/support/apply/countries-eligible-for-support/.
  17. Vaccine price commitments from manufacturers [Internet]. 2015 [cited Accessed 28 May 2016]. Available from: http://www.gavi.org/library/gavi-documents/supply-procurement/vaccine-price-commitments-from-manufacturers/.
  18. Levin CE, Van Minh H, Odaga J, Rout SS, Ngoc DN, Menezes L, et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull World Health Organ. 2013;91(8):585–92.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine. 2008;26(32):4015–24.View ArticlePubMedGoogle Scholar
  20. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406–14.View ArticlePubMedGoogle Scholar
  21. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effective analysis. Geneva: World Health Organization; 2003.Google Scholar
  22. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89:821–30B.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health. 2009;9:29.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Le P, Griffiths UK, Anh DD, Franzini L, Chan W, Swint JM. Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam. Vaccine. 2015;33(36):4639–46.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. PharmacoEconomics. 2014;32(6):525–31.View ArticlePubMedGoogle Scholar
  26. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization. 2015;93(2):118–24.View ArticlePubMedGoogle Scholar
  27. Jit M, Dang TT, Friberg I, Hoang VM, Pham Huy TK, Walker N, et al. Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national expanded programme on immunization. Vaccine. 2015;33 Suppl 1:A233–9.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Bui NC, Kim GB, Nguyen TH, Nguyen LH, Van Hoang M. Willingness to pay for a quality adjusted life year in Bavi district, Hanoi 2014. Vietnam J Public Health. 2014;2(2):42.Google Scholar
  29. Poulos C, Yang JC, Levin C, Van Minh H, Giang KB, Nguyen D. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Social Sci Med (1982). 2011;73(2):226–34.View ArticleGoogle Scholar
  30. Herlihy N, Hutubessy R, Jit M. Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. Health Affairs (Project Hope). 2016;35(2):227–34.View ArticleGoogle Scholar
  31. Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31(37):3786–804.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement